Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the activation of its first U.S. clinical trial site to evaluate PBGENE-HBV as part of the ELIMINATE-B Phase 1 clinical trial. The newly activated site at Massachusetts General Hospital in Boston, Massachusetts, is now actively recruiting patients. ". ...